GlassScriptPhysician profile
Robert L Villalobos
NPI 1285682674
$1,682.98
in general payments reported to CMS, 2019-2025
15 companies · $377 in 2025
The $377 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $28.89 · 2021: $259 · 2022: $317 · 2023: $191 · 2024: $333 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $473.56 | 2021-2024 | Iluvien, Yutiq |
| Allergan, INC. | $238.10 | 2019-2021 | |
| Abbvie INC. | $193.29 | 2022-2025 | Durysta |
| Dompe US, INC. | $173.79 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $173.04 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $86.87 | 2024-2025 | Acthar |
| Horizon Therapeutics Plc | $66.73 | 2021-2023 | Tepezza |
| Astellas Pharma US INC | $50.60 | 2025 | Izervay |
| Alcon Vision LLC | $50.14 | 2021-2025 | Eysuvis |
| Glaukos Corporation | $49.06 | 2025 | Idosetr |
| Harrow Eye, LLC | $31.12 | 2025 | Triesence |
| Novartis Pharmaceuticals Corporation | $29.49 | 2020-2021 | |
| Amgen INC. | $29.04 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $21.42 | 2019 | |
| Oyster Point Pharma, INC. | $16.73 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Villalobos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.